healthŌme™ Inc. announced earlier this week its acquisition of Kailos Genetics, LLC for an undisclosed price.
Kailos Genetics is a CLIA-certified and CAP-accredited genetic testing laboratory and supplier of clinical grade laboratory reagents for next-generation sequencing.
healthŌme is a leading genomics-based, health navigation company based at the HudsonAlpha Institute for Biotechnology in Huntsville, Alabama. healthŌme, in partnership with Hannover Re US, the reinsurer for healthŌme’s new first-of-its-kind, patent pending cancer program, designs, develops and delivers its health management solutions through a network of life and critical insurance carriers.
With the acquisition, Kailos Genetics diversifies its laboratory services business model beyond the confines of traditional healthcare reimbursement and payer systems. The acquisition opens doors to new markets through the life and critical insurance industry distribution channels, where healthŌme products are prominently sold. With this, Kailos Genetics gains a wider market reach for its testing services, unlocking new growth opportunities and establishing a foundation for future success.
The integration process will commence immediately, with a focus on maintaining uninterrupted services for existing customers while continuing to explore opportunities for expanding service offerings.
According to data captured in the LevinPro HC database, this acquisition marks 60th Laboratories, MRI and Dialysis transaction of the year, 30 of them in the diagnostics subsector. This transaction is MedGenome’s first acquisition since it purchased Trident Diagnostics & Healthcare Pvt Ltd in November 2021.
